Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Director | May 22, 2024 | May 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mineralys Therapeutics, Inc.
Report date May 22, 2024 · Filed May 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.52 · Expires 2034-05-22 | Direct | 22,000 |
Reported balance
After 2024-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-22 · Grant · Acquired 22,000 · Balance 22,000 F1: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2024 Filed May 23, 2024 20:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 22,000 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001933414-24-000018 · wk-form4_1716495632.xml · derivative · entry 1 Litzka Olivier · CIK 0001963940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting. Read SEC document |
| April 27, 2023 Filed May 1, 2023 20:06 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherStock Option · Derivative | 44,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001933414-23-000026 · wf-form4_168297155965134.xml · derivative · entry 1 Litzka Olivier · CIK 0001963940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2033-02-09 F1 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and BioDiscovery 6 FCPI. F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 02:02 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 44,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001628280-23-003428 · wf-form4_167634014769384.xml · derivative · entry 1 Litzka Olivier · CIK 0001963940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2033-02-09 F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.